NHS to receive £250m for new AI lab
marbury / Shutterstock.com
The National Health Service (NHS), the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme (MSD) and AbbVie to help eliminate hepatitis C in England.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
National Health Service, NHS, Gilead Sciences, Merck Sharp Dohme, MSD, AbbVie, Hepatitis C, life sciences